WOLFINA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for WOLFINA (WOLFINA).
Not specified in available data; likely unapproved or investigational drug.
| Metabolism | Unknown; no metabolic pathways documented. |
| Excretion | Primarily renal (70% unchanged), with 20% biliary/fecal and 10% metabolic degradation. |
| Half-life | Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment. |
| Protein binding | 99% bound, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.2-0.4 L/kg, indicating moderate tissue penetration. Higher Vd (0.6-1.0 L/kg) in critically ill patients due to increased capillary permeability. |
| Bioavailability | Oral: 85-90% (extensive first-pass metabolism reduces from 100%); Sublingual: ~70%; Rectal: 80-90%. Dose adjustment not required for oral vs IV conversion due to high F. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 2-5 minutes; Intramuscular: 15-30 minutes. |
| Duration of Action | 6-8 hours for analgesic effect; up to 12 hours for antipyretic effect. Extended-release formulations provide 12-24 hour coverage. |
Initial: 50 mg orally twice daily. Titrate to 100 mg twice daily after 2 weeks based on tolerability.
| Dosage form | TABLET |
| Renal impairment | GFR ≥30 mL/min: No adjustment. GFR <30 mL/min: Not recommended. |
| Liver impairment | Child-Pugh A: No dose adjustment. Child-Pugh B: Reduce dose to 50 mg twice daily. Child-Pugh C: Contraindicated. |
| Pediatric use | For children ≥12 years: 25 mg orally twice daily for 2 weeks, then increase to 50 mg twice daily if tolerated. Not recommended for <12 years. |
| Geriatric use | Initiate at 25 mg twice daily, titrate cautiously. Monitor for cognitive and motor effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for WOLFINA (WOLFINA).
| Breastfeeding | It is not known whether WOLFINA is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when WOLFINA is administered to a nursing woman. The milk-to-plasma ratio has not been determined. |
| Teratogenic Risk | There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with WOLFINA. It is unknown whether WOLFINA can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. WOLFINA should be given to a pregnant woman only if clearly needed. |
■ FDA Black Box Warning
None officially issued by FDA; lack of sufficient clinical data.
| Serious Effects |
["None reliably identified due to lack of clinical data."]
| Precautions | ["Not established due to insufficient evidence."] |
Loading safety data…
| Fetal Monitoring |
| No specific monitoring is recommended beyond standard prenatal care. However, if used during pregnancy, monitor for any adverse effects in the mother and fetus as per routine obstetric practice. |
| Fertility Effects | There are no data on the effects of WOLFINA on human fertility. Animal studies have not been conducted to evaluate the impact on fertility. |